financetom
Business
financetom
/
Business
/
ED Director Sanjay Kumar Mishra's tenure ends, Rahul Navin appointed in-charge chief
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ED Director Sanjay Kumar Mishra's tenure ends, Rahul Navin appointed in-charge chief
Sep 15, 2023 2:42 PM

IRS officer Rahul Navin was appointed as in-charge director of the Enforcement Directorate on Friday on the completion of tenure of the incumbent Sanjay Kumar Mishra, officials said.

According to an official order, Navin, a 1993-batch IRS officer, will hold the charge till the appointment of a regular director or until further orders. Navin is currently the ED’s special director.

The order stated that the President "is pleased to order the cessation of tenure of Sanjay Kumar Mishra…as Director of Enforcement in the Enforcement Directorate on 15.09.2023." On July 26, the Supreme Court granted an extension of tenure to ED chief Mishra till September 15 but made it clear there would be no further extension.

The SC order came days after it had held as "illegal" two successive extensions of one year each granted to ED director Mishra, an IRS officer of 1984 cadre, saying these were in ”breach” of its mandamus in the 2021 verdict that the IRS officer should not be given further term.

The 1984-batch IRS officer was otherwise to remain in office till November 18, 2023, according to the notification issued by the government.

The verdict on a batch of petitions, including those filed by Congress leaders Randeep Singh Surjewala and Jaya Thakur, and TMC leaders Mahua Moitra and Saket Gokhale, challenging the extensions granted to Mishra.

Mishra was first appointed the ED director for two years on November 19, 2018. Later, by an order dated November 13, 2020, the central government modified the appointment letter retrospectively and his two-year term was changed to three years.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
FOCUS-Wall Street hires more senior bankers as growing confidence spurs deal rebound
FOCUS-Wall Street hires more senior bankers as growing confidence spurs deal rebound
Aug 25, 2025
* Hiring surge follows tariff-induced pause * Senior hires include Citigroup ( C/PN ) and UBS executives * Junior staff recruitment rose 200% in August, search firm says By Tatiana Bautzer, Saeed Azhar and Isla Binnie NEW YORK, Aug 25 (Reuters) - Wall Street banks have hired dozens of senior executives in recent months, as improved economic sentiment has spurred...
BRIEF-Beigene And Unit Sign Royalty Purchase Agreement With Royalty Pharma PLC's Unit
BRIEF-Beigene And Unit Sign Royalty Purchase Agreement With Royalty Pharma PLC's Unit
Aug 25, 2025
Aug 25 (Reuters) - Beigene Ltd: * SAY CO, UNIT SIGN ROYALTY PURCHASE AGREEMENT WITH ROYALTY PHARMA INVESTMENTS 2023 ICAV, UNIT OF ROYALTY PHARMA PLC * SAYS AGREED TO SELL RIGHTS TO ROYALTIES ON IMDELLTRA SALES OUTSIDE CHINA TO ROYALTY PHARMA INVESTMENTS 2023 ICAV FOR $885 MILLION UPFRONT Source text Further company coverage: (Reporting by Beijing Newsroom) ...
Temu-owner PDD tops quarterly revenue estimates
Temu-owner PDD tops quarterly revenue estimates
Aug 25, 2025
(Reuters) -Chinese e-commerce firm PDD Holdings ( PDD ) beat market estimates for quarterly revenue on Monday, signaling a rebound in domestic demand and improved growth in its international business despite global trade uncertainties. U.S.-listed shares of the company jumped nearly 12% in premarket trading. The Chinese government has been seeking to boost domestic consumption to revive a sluggish economy...
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
Aug 25, 2025
(Reuters) -Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million. The deal gives Royalty Pharma access to roughly 7% of global net sales of the therapy, which won U.S. approval last year for patients with extensive-stage small cell...
Copyright 2023-2026 - www.financetom.com All Rights Reserved